Enquirer Consulting Group

Reachable Buyer Map

Prepared for Weisheng Chen · Leveragen · September 2026
Here is the map Ishmael promised. Leveragen says it partners with biotechnology, pharmaceutical and academic organizations, through platform licensing, integrated antibody discovery services and genetic engineering work, with applications across therapeutics, diagnostics and animal health. So this page maps the US buyers around that offer: which groups of organizations they sit in, who inside each one holds the decision, and roughly how many exist. It maps the market around Leveragen, not Leveragen itself, and there is nothing to buy at the end of it.
Where the buying decision actually sits
Eight rows, ordered from the programs closest to the clinic out to the edges of the market. Counts are banded on purpose and count organizations, not people or programs. The four trial rows overlap, because one company can run programs in more than one modality.
Multispecific antibody developers in the clinic
Companies with at least one bispecific, trispecific or multispecific antibody in a registered trial. A company with a multispecific already in the clinic is a company that builds, buys or licenses binders for that format, and it needs more of them for whatever comes next in its pipeline.
Who holds it: at an emerging biotech, the CSO or the head of antibody discovery or protein engineering. At a large or mid-size pharma company, the biologics research lead signs off on the science and a search and evaluation or external innovation team runs the deal.
Who holds the license: business development and licensing. A platform license and a discovery program are usually decided by different people inside the same company.
About 80
companies sponsoring at least one trial with a US site, started since 2021, that names a multispecific format. A floor: programs that have not reached the clinic do not appear.
Antibody-drug conjugate developers in the clinic
An ADC program starts with the antibody. These teams already have a payload and linker strategy, so what they look for from outside is the binder that carries it to a new target.
Who holds it: the head of biologics or antibody discovery, often alongside a conjugation or ADC platform lead. At a large company, the external innovation or search and evaluation group runs the deal.
About 85
companies sponsoring at least one trial with a US site, started since 2021, that names an antibody-drug conjugate. Same floor as the row above.
Engineered cell therapy developers
CAR-T, CAR-NK and related programs. Your own site describes single-domain antibodies as key components for cell therapies, and this is the group that builds those therapies.
Who holds it: the CSO or VP of research, and a head of binder discovery or protein engineering where that seat exists. Where the company is small, the scientific founder often still decides.
About 90
companies sponsoring at least one trial with a US site, started since 2021, that names a chimeric antigen receptor program.
Every antibody sponsor in US trials
The wider pool: any company with a monoclonal, bispecific or conjugated antibody in a US trial. It runs from the largest pharma companies to a long tail of single-asset biotechs.
Who holds it: the same seats as above. In a single-asset company, that is often one person: the CSO or the founder.
About 400
distinct companies, counted once each. The ADC row sits inside it, and so do the bispecific programs in the first row. International companies running trials at US sites are included.
Preclinical biotech companies
The part of the market a trial registry cannot see, because these companies have nothing in the clinic yet. It is also the natural buyer for genetic engineering work: knockout, knock-in and humanized models for in vivo studies. The count is every registered biotech R&D company, not just antibody companies, so it is a pool to filter rather than a target.
Who holds it: the scientific founder or CSO in most companies this size. Where there is a head of in vivo pharmacology, they brief the model work and the CSO signs.
Close to home: about 330 of these name biotech R&D as their main line in Massachusetts alone.
3,200 to 7,400
federally registered US companies. About 3,200 name biotechnology R&D as their primary line of business, and about 7,400 list it anywhere.
Diagnostic and research antibody makers
Companies that turn antibodies into a product rather than a pipeline: diagnostic test makers and research reagent suppliers. Your platform page names diagnostics as an application. These buyers need a binder that performs in an assay, on a product timeline rather than a clinical one.
Who holds it: the VP of R&D or head of assay or reagent development, with business development involved once licensing terms come up.
300 to 950
federally registered US companies. About 300 name in vitro diagnostic manufacturing as their primary line, and about 950 list it anywhere. Research reagent suppliers file under several codes and are only partly inside this count.
Academic single-domain antibody groups
Your partnerships page names academic organizations as partners. These are the universities, hospitals and research institutes running federally funded projects built on nanobodies or single-domain antibodies right now. They buy for research use out of a grant, and they take commercial rights through a technology transfer office.
Who holds it: the principal investigator for research use. The technology transfer office for any license with commercial rights attached.
About 120
organizations holding at least one federally funded single-domain antibody project in the last two fiscal years. About 105 are universities, hospitals and institutes, the rest small companies. About 15 are in Massachusetts.
Animal health biologics
Your platform page lists dog and cat scaffolds for animal health. The buyers here are companion animal therapeutics developers and veterinary biologics makers. This group cannot be counted from the registries this page uses, because they file animal and human biologics under the same business code. Rather than show a number built on that mix, this row carries none.
Who holds it: the head of R&D or biologics at a companion animal company, and business development for licensing.
No public count
the business registries do not separate animal health biologics from human ones, so this segment is built by name rather than counted.

Where the openings are

1
The clinic rows are small enough to work in full, by name. About 220 distinct companies sit across the multispecific, ADC and cell therapy rows. Every one of them is named in a public trial record, next to the program it is running. So a first message can reference the actual modality and disease area rather than a generic line about antibody discovery, and a list that size can be worked completely rather than sampled.
2
Licensing and discovery services are sold to different seats, so each account has two doors. Leveragen offers platform licenses, discovery programs and combinations of the two. Inside a pharma company or a mid-size biotech, the license conversation runs through business development or search and evaluation, and the discovery program runs through the head of antibody or protein science. Reaching only one of those seats leaves half of the offer unheard.
3
Diagnostics and research reagents are counted in the hundreds, not the thousands. Your own site names diagnostics and animal health as applications. Segments that size, and the animal health group that cannot be counted at all, are built by naming the companies one at a time against a signal, such as a new assay launch or a new companion animal program, and that filtering step is what turns a market into a working list.
Built from public federal registries and the public clinical trial registry, current to September 2026, with business registrations current to July 2026. Counts are banded deliberately. Trial counts are companies, counted once each, sponsoring at least one trial with a US site started since 2021, so programs still in discovery are not included. Business registration counts are companies by their stated line of business, and a segment with no credible public number says so rather than showing one.
ENQUIRER CONSULTING GROUP
enquirerconsulting.com